These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20687889)

  • 21. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.
    Lagathu C; Béréziat V; Gorwood J; Fellahi S; Bastard JP; Vigouroux C; Boccara F; Capeau J
    Expert Opin Drug Saf; 2019 Sep; 18(9):829-840. PubMed ID: 31304808
    [No Abstract]   [Full Text] [Related]  

  • 22. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.
    Addy CL; Gavrila A; Tsiodras S; Brodovicz K; Karchmer AW; Mantzoros CS
    J Clin Endocrinol Metab; 2003 Feb; 88(2):627-36. PubMed ID: 12574192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
    Grinspoon SK
    Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection.
    Calza L; Masetti G; Piergentili B; Trapani F; Cascavilla A; Manfredi R; Colangeli V; Viale P
    Int J STD AIDS; 2011 Jan; 22(1):43-5. PubMed ID: 21364066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pathogenic mechanisms for fat redistribution in patients with HIV disease].
    Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):657-61. PubMed ID: 17571562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies.
    Koutkia P; Grinspoon S
    Annu Rev Med; 2004; 55():303-17. PubMed ID: 14746523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.
    Vigouroux C; Maachi M; Nguyên TH; Coussieu C; Gharakhanian S; Funahashi T; Matsuzawa Y; Shimomura I; Rozenbaum W; Capeau J; Bastard JP
    AIDS; 2003 Jul; 17(10):1503-11. PubMed ID: 12824788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
    Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
    Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.
    Benedini S; Terruzzi I; Lazzarin A; Luzi L
    BioDrugs; 2008; 22(2):101-12. PubMed ID: 18345707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.
    Chen D; Misra A; Garg A
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.
    Kolter DP
    AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of anti-retroviral therapy on body composition changes: a literature review].
    Dell'Isola C; Aprea L; Pizzella T; Izzo C
    Infez Med; 2006 Mar; 14(1):5-12. PubMed ID: 16794374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.
    Willig AL; Overton ET
    Curr HIV/AIDS Rep; 2016 Oct; 13(5):289-96. PubMed ID: 27541600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy.
    Yang Y; Yap M; Oo Tha N; Paton NI
    HIV Clin Trials; 2008; 9(6):399-406. PubMed ID: 19203905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults.
    Monier PL; Wilcox R
    Am J Med Sci; 2004 Jul; 328(1):48-56. PubMed ID: 15254441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body-fat abnormalities in patients with HIV: progress and challenges.
    Bedimo RJ
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):292-305. PubMed ID: 19056708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.